Company Profile
Cytokinetics Stock Price, News & Catalysts
- Ticker:
- CYTK
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
75.87 USD (+2.35%)
Close
Last updated: August 17, 2026
9.63B USD
Market cap
Why the stock is moving
The latest monitored company update is “Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).” The corresponding closing-price reaction is not yet available.
Company overview
Muscle Biology Specialization
Cytokinetics develops and commercializes medicines that modulate muscle function. Its portfolio is centered on cardiac muscle biology and diseases in which altered contractility contributes directly to symptoms and clinical outcomes.
MYQORZO in Obstructive HCM
MYQORZO, or aficamten, is a cardiac myosin inhibitor approved in the United States and European Union for adults with symptomatic obstructive hypertrophic cardiomyopathy. The product launched in the United States in January 2026 and forms the company’s emerging commercial franchise.
Aficamten Lifecycle Development
Cytokinetics is seeking to broaden aficamten across hypertrophic cardiomyopathy. The Phase 3 ACACIA-HCM trial met its dual primary endpoints in symptomatic non-obstructive HCM, while MAPLE-HCM supports a supplemental application in obstructive disease and additional studies address Japanese patients.
Heart-Failure Pipeline
Omecamtiv mecarbil is a cardiac myosin activator in the confirmatory Phase 3 COMET-HF trial for symptomatic heart failure with severely reduced ejection fraction. This program extends the company’s muscle-directed approach beyond HCM.
Future catalysts
- Initial European launch of MYQORZO in Germany expected in the second quarter of 2026.
- FDA action on the aficamten supplemental NDA supported by MAPLE-HCM expected by November 14, 2026.
- Full results from the Phase 3 ACACIA-HCM trial to be presented at a medical congress.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Cytokinetics (CYTK)?
Cytokinetics (CYTK) most recently closed at 75.87 USD, a +2.35% move versus the previous session.
What is the market cap of Cytokinetics (CYTK)?
Cytokinetics currently has a market capitalization of 9.63B USD on BioPharmSignal.
What does Cytokinetics do?
Muscle Biology Specialization Cytokinetics develops and commercializes medicines that modulate muscle function. Its portfolio is centered on cardiac muscle biology and diseases in which altered contractility contributes directly to symptoms and clinical outcomes. MYQORZO in Obstructive HCM MYQORZO, or aficamten, is a cardiac myosin inhibitor approved in the...
On which exchange is CYTK stock listed?
Cytokinetics (CYTK) is associated with NASDAQ, United States, Biopharma.
What is ACACIA-HCM?
Full results from the Phase 3 ACACIA-HCM trial to be presented at a medical congress.
Which conditions is Cytokinetics targeting with ACACIA-HCM?
Full results from the Phase 3 ACACIA-HCM trial to be presented at a medical congress.
How does Cytokinetics describe recent progress with ACACIA-HCM?
Full results from the Phase 3 ACACIA-HCM trial to be presented at a medical congress.
What is MAPLE-HCM?
The Phase 3 ACACIA-HCM trial met its dual primary endpoints in symptomatic non-obstructive HCM, while MAPLE-HCM supports a supplemental application in obstructive disease and additional studies address Japanese patients.